Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 10/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | IL1B | P01584 | 1/20 | 0.34 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.34 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412858 | 0.89 | CYP1A2 (0.43) | CYP1A2P2RX7IL1B | |
| SCHEMBL1412841 | 0.86 | P2RX7 (0.38) | CYP1A2P2RX7IL1BSLC6A9PDE2A | |
| SCHEMBL1412986 | 0.80 | P2RX7 (0.37) | P2RX7 | |
| SCHEMBL1413090 | 0.76 | P2RX7 (0.35) | P2RX7SLC6A9 | |
| SCHEMBL1412960 | 0.76 | P2RX7 (0.50) | P2RX7 | |
| SCHEMBL1412914 | 0.70 | P2RX7 (0.36) | P2RX7SLC6A9 | |
| SCHEMBL1413002 | 0.68 | P2RX7 (0.47) | CYP1A2P2RX7 | |
| SCHEMBL1412895 | 0.67 | P2RX7 (0.39) | P2RX7 | |
| SCHEMBL1412873 | 0.66 | P2RX7 (0.45) | P2RX7ELOVL6 | |
| SCHEMBL1412859 | 0.66 | P2RX7 (0.34) | P2RX7RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1448535-B1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PROD INC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-7235549-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-7214677-B2 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. (US) | 2007-05-08 | — | — | US | disclosed |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2006-03-16 | — | — | US | disclosed |
| CN-1585755-A | Benzamide and heteroarylamide as P2X7 receptor antagonists | PFIZER PROD INC (US) | 2005-02-23 | — | — | CN | disclosed |
| EP-1448535-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2004-08-25 | — | — | EP | disclosed |
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | PFIZER INC. | 2003-10-02 | — | — | US | disclosed |
| WO-2003042191-A1 | BENZAMIDE AND HETEROARYLAMIDE AS P2X7 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186981-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | CYP1A2 681/4885P2RX7 1/4885RIPK1 2587/4885 |
| US-20060058302-A1 | Benzamide, heteroarylamide and reverse amides | P2RX7, P2RX5, P2RX2 | CYP1A2 938/4885P2RX7 1/4885RIPK1 1211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.